Molecular diagnostics platform Xagenic, backed by peer Qiagen and spun out of University of Toronto, boosted its total funding to more than $52m in the round.

Xagenic, a Canada-based molecular diagnostics company backed by biotechnology company Qiagen, secured $15m in its series C round yesterday.

The round included backing from Domain Associates, CTI Life Sciences and Ontario government-backed Ontario Capital Growth, as well as BDC Capital, a subsidiary of state-backed Business Development Bank of Canada.

Xagenic has developed a platform called Xagenic X1 that enables users to conduct lab-quality molecular tests in a general practitioner’s surgery. The platform, which is based on research at University of…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?